Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY451395 for Aggression and Agitation in Alzheimer's Disease
NCT00843518Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Feb 2009
- Primary completion
- Jun 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of mibampator in Alzheimer's disease (AD), sponsored by Eli Lilly and Company. Started Feb 2009; status: completed.
02
Drugs
mibampator
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT00843518.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00843518.